Laurence Levine to Clostridium histolyticum
This is a "connection" page, showing publications Laurence Levine has written about Clostridium histolyticum.
Connection Strength
1.133
-
Re: Re: Limited success with clostridium collagenase histolyticum following FDA approval for the treatment of Peyronie's disease. Int J Impot Res. 2020 03; 32(2):257-258.
Score: 0.683
-
Characteristics of Men With Peyronie's Disease and Collagenase Clostridium Histolyticum Treatment Failure: Predictors of Surgical Intervention and Outcomes. J Sex Med. 2020 05; 17(5):1005-1011.
Score: 0.177
-
Clinical safety and effectiveness of collagenase clostridium histolyticum injection in patients with Peyronie's disease: a phase 3 open-label study. J Sex Med. 2015 Jan; 12(1):248-58.
Score: 0.123
-
Surgical correction of persistent Peyronie's disease following collagenase clostridium histolyticum treatment. J Sex Med. 2015 Jan; 12(1):259-64.
Score: 0.122
-
Baseline characteristics from an ongoing phase 3 study of collagenase clostridium histolyticum in patients with Peyronie's disease. J Sex Med. 2013 Nov; 10(11):2822-31.
Score: 0.028